arrow
返回
D

David G. Warnock

University of Alabama System

67H指数
330论文数
2.3W被引数
收录论文 136
发表时间
Assessment of immunogenicity from the pegunigalsidase alfa clinical trial program: Integrated analysis of de novo and treatment-boosted anti-drug antibodies
err2024-02-01
err0
PREAI
errBernat, John; Hughes, Derralynn; Linhart, Ales; Hopkin, Robert J.; Tondel, Camilla; Warnock, David G.; Rup, Bonita; Koulinska, Irene; Rocco, Rossana; Alon, Sari; Chertkoff, Raul; Almon, Einat Brill; Sakov, Anat; Wallace, Eric
err分享
err收藏
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study
err2023-11-08
err24
errOAAI
errWallace, Eric L.; Goker-Alpan, Ozlem; Wilcox, William R.; Holida, Myrl; Bernat, John; Longo, Nicola; Linhart, Ales; Hughes, Derralynn A.; Hopkin, Robert J.; Tondel, Camilla; Langeveld, Mirjam; Giraldo, Pilar; Pisani, Antonio; Germain, Dominique Paul; Mehta, Ankit; Deegan, Patrick B.; Molnar, Maria Judit; Ortiz, Damara; Jovanovic, Ana; Muriello, Michael; Barshop, Bruce A.; Kimonis, Virginia; Vujkovac, Bojan; Nowak, Albina; Geberhiwot, Tarekegn; Kantola, Ilkka; Knoll, Jasmine; Waldek, Stephen; Nedd, Khan; Karaa, Amel; Brill-Almon, Einat; Alon, Sari; Chertkoff, Raul; Rocco, Rossana; Sakov, Anat; Warnock, David G.
err分享
err收藏
Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease
err2023-05-05
err4
errOAAI
errNikolaenko, Valeria; Warnock, David G.; Mills, Kevin; Heywood, Wendy E.
err分享
err收藏
First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study
err2023-02-01
err1
PREAI
errWallace, Eric; Goker-Alpan, Wilcox; Holida, Bernat; Longo, N.; Hughes, D.; Giraldo, P.; Molnar, M. J.; Ortiz, Hopkin; Tondel, C.; Linhart, A.; Deegan, Jovanovic; Muriello, M.; Barshop, Kimonis; Vujkovac, B.; Nowak, A.; Geberhiwot, T.; Pisani, A.; Germain, D. P.; Kantola, I.; Knoll, J.; Mehta, Ankit; Waldek, Stephen; Chertkoff, Raul; Almon, Einat; Alon, Sari; Rocco, Rossana; Warnock, David G.
err分享
err收藏
Estimation of arrhythmia risk in patients with Fabry disease using a machine learning model
err2023-02-01
err0
PREAI
errAguiar, Patricio; Biondetti, Giorgio Pietro; Warnock, David G.; Kallish, Staci; Nelson, Matthew W.; Giuliano, Joseph; Zabinski, Joseph W.; Boussios, Costas; Curhan, Gary; Bandaria, Jigar N.; Gliklich, Richard E.; Jefferies, John L.
err分享
err收藏
Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Twoyear interim results from the ongoing phase 3 BRIGHT51 openlabel extension study
err2023-02-01
err0
PREAI
errBernat, John; Holida, Myrl D.; Longo, Nicola; Goker-Alpan, Ozlem; Wallace, Eric; Deegan, Patrick B.; Tondel, Camilla; Eyskens, Francois J.; Feldt-Rasmussen, Ulla; Hughes, Derralynn; Pisani, Antonio; Rocco, Rossana; Almon, Einat Brill; Alon, Sari; Chertkoff, Raul; Warnock, David G.; Waldek, Stephen; Wilcox, William R.
err分享
err收藏
Safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: Results from the phase 3, open-label, BRIGHT study
err2022-03-01
err4
errOAAI
errBernat, John; Holida, Myrl; Longo, Nicola; Goker-Alpan, Ozlem; Wallace, Eric; Deegan, Patrick; Nedd, Khan; Tondel, Camilla; Eyskens, Francois; Feldt-Rasmussen, Ulla; Pisani, Antonio; Rocco, Rossana; Almon, Einat; Alon, Sari; Chertkoff, Raul; Warnock, David; Waldek, Stephen; Wilcox, William
err分享
err收藏
A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm
err2021-12-20
err24
errOAAI
errJefferies, John L.; Spencer, Alison K.; Lau, Heather A.; Nelson, Matthew W.; Giuliano, Joseph D.; Zabinski, Joseph W.; Boussios, Costas; Curhan, Gary; Gliklich, Richard E.; Warnock, David G.
err分享
err收藏
Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus
err2021-04-01
err9
errOAAI
errMoreno-Martinez, D.; Aguiar, P.; Auray-Blais, C.; Beck, M.; Bichet, D. G.; Burlina, A.; Cole, D.; Elliott, P.; Feldt-Rasmussen, U.; Feriozzi, S.; Fletcher, J.; Giugliani, R.; Jovanovic, A.; Kampmann, C.; Langeveld, M.; Lidove, O.; Linhart, A.; Mauer, M.; Moon, J. C.; Muir, A.; Nowak, A.; Oliveira, J. P.; Ortiz, A.; Pintos-Morell, G.; Politei, J.; Rozenfeld, P.; Schiffmann, R.; Svarstad, E.; Talbot, A. S.; Thomas, M.; Tondel, C.; Warnock, D.; West, M. L.; Hughes, D. A.
err分享
err收藏
Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
err2021-01-25
err43
errOAAI
errNowak, Albina; Beuschlein, Felix; Sivasubramaniam, Visnuka; Kasper, David; Warnock, David G.
err分享
err收藏
Current and Investigational Therapeutics for Fabry Disease
err2020-04-01
err65
errOAAI
errFelis, Andrew; Whitlow, Michael; Kraus, Abigayle; Warnock, David G.; Wallace, Eric
err分享
err收藏
Pegunigalsidase alfa, a novel PEGylated ERT, evaluated in Fabry disease patients with progressing kidney disease, RCT study design
err2020-02-01
err0
PREAI
errWarnock, David G.; Hughes, Derralynn; Alon, Sari; Chertkoff, Raul; Brill-Almon, Einat; Schiffmann, Raphael
err分享
err收藏
Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease
err2019-09-13
err25
errOAAI
errDoykov, Ivan D.; Heywood, Wendy E.; Nikolaenko, Valeria; Spiewak, Justyna; Hallqvist, Jenny; Clayton, Peter Theodore; Mills, Philippa; Warnock, David G.; Nowak, Albina; Mills, Kevin
err分享
err收藏
Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa phase III BALANCE study
err2019-02-01
err2
errOAAI
errWarnock, David; Eric, Wallace; Schiffmann, Raphael; Holida, Myrl; Goker-Alpan, Ozlem; Hopkin, Robert; Giraldo, Pilar; Khan, Nedd; Vujkovac, Bojan; Wilcox, William; Linhart, Ales; Tondel, Camilla; Barshop, Bruce A.; Karaa, Amel; Molnar, Maria Judit; Deegan, Patrick; Vockley, Jerry; Rhead, William; Kimonis, Virginia; Chertkoff, Raul; Longo, Nicola
err分享
err收藏
Urinary Tubular Injury Biomarkers Are Associated With ESRD and Death in the REGARDS Study
err2018-09-01
err16
errOAAI
errDubin, Ruth F.; Judd, Suzanne; Scherzer, Rebecca; Shlipak, Michael; Warnock, David G.; Cushman, Mary; Sarnak, Mark; Parikh, Chirag; Bennett, Michael; Powe, Neil; Peralta, Carmen A.
err分享
err收藏
Enhanced pharmacokinetics profile of pegunigalsidase alfa (PRX-102) supports once-monthly 2mg/kg dosing for the treatment of Fabry disease
err2018-02-01
err1
PREAI
errWarnock, David G.; Charney, Martha R.; Hughes, Derralynn; Schiffmann, Raphael; Alon, Sari; Chertkoff, Raul; Brill-Almon, Einat
err分享
err收藏
A survivor analysis for major clinical events in heterozygous female patients with Fabry disease using group consensus phenotype classifications from hemizygous male patients
err2018-02-01
err1
PREAI
errHopkin, Robert J.; Germain, Dominique P.; Bichet, Daniel G.; Gruskin, Daniel J.; Lemay, Roberta M.; Oliveira, Joao P.; Politei, Juan M.; Wanner, Christoph; Wilcox, William R.; Yoo, Han-Wook; Warnock, David G.
err分享
err收藏